Skip to main content
OpenTrials
Completed

NCT Number: NCT05542017

Long-term Outcome Following Concomitant Surgical Ablation for Atrial Fibrillation at University Hospital Basel: A Retrospective Study

This retrospective single-centre study aims to examine the success rate of concomitant surgical ablation in patients with atrial fibrillation (AF) with an up to eight years follow-up period. Moreover, the focus of this study was to identify variables which predict freedom from AF, such as the type of AF, lesion set performed, energy source used and the patient's characteristics.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Atrial Fibrillation Arrhythmias, Cardiac Cardiovascular Diseases Heart Diseases Maze Procedure Pathologic Processes Pathological Conditions, Signs and Symptoms

Sex eligibility

All sexes

Study type

Observational

Primary location

University Hospital Basel

Basel, Canton of Basel-City, 4031, Switzerland

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • concomitant surgical ablation for atrial fibrillation
  • performed between January 2011 and January 2017 at University Hospital Basel

Exclusion criteria

  • stand-alone procedure
  • surgical ablation for atrial flutter

Treatment and study plan

Surgical Ablation for Atrial Fibrillation

Procedure

Surgical ablation in combination with other cardiac procedures through a median sternotomy or thoracotomy. Main procedures were valve surgery (i.e. repair, replacement) and/or coronary artery bypass grafting (CABG). Surgical ablation procedures for atrial fibrillation were divided into three different groups according to Heart Rhythm Society (HRS) expert consensus 2017: (1) Pulmonary vein isolation alone; (2) Pulmonary vein isolation combined with left atrial lesion sets; (3) and biatrial procedure.

Primary outcomes

  1. Freedom from AF one year after surgical ablation

    Time frame: 12 months

    one-year success

Secondary outcomes

  1. Freedom from atrial fibrillation (AF) and atrial flutter (AFL) after removal from antiarrhythmic drug therapy

    Time frame: from surgical ablation until 10th October 2019

  2. Need of additional arrhythmia interventions

    Time frame: from surgical ablation until 10th October 2019

    repeat ablation procedures, electrical cardioversion, pacemaker implantation or implantable cardioverter-defibrillator (ICD) implantation

  3. Use of oral anticoagulation

    Time frame: from surgical ablation until 10th October 2019

  4. Perioperative morbidity

    Time frame: from surgical ablation until 10th October 2019

  5. Mortality

    Time frame: from surgical ablation until 10th October 2019

  6. Evolution of left atrial size

    Time frame: from surgical ablation until 10th October 2019

Sponsors and collaborators

Lead sponsor

University Hospital, Basel, Switzerland

Other

Registry information

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Sep 15, 2022
Registry last updated
Sep 26, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.